Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.

Erik Berntorp; C Negrier; P Gozzi; P-M Blaas; S Lethagen

doi:10.1111/hae.12887

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.

Erik Berntorp, C Negrier, P Gozzi, P-M Blaas, S Lethagen

Clinical Coagulation, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

To use Pharmacokinetic (PK) simulations to illustrate potential differences in clinical outcomes between prophylaxis with conventional recombinant factor VIII (rFVIII) and rFVIIIFc, an extended half-life rFVIII covalently fused to the Fc domain of human IgG1.

Original language	English
Journal	Haemophilia
Early online date	2016 Feb 11
DOIs	https://doi.org/10.1111/hae.12887
Publication status	Published - 2016

Subject classification (UKÄ)

Hematology

Access to Document

10.1111/hae.12887

http://www.ncbi.nlm.nih.gov/pubmed/26863900?dopt=Abstract

Cite this

@article{7bf7d1641e294fee8a80c0d312ba47d7,

title = "Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.",

abstract = "To use Pharmacokinetic (PK) simulations to illustrate potential differences in clinical outcomes between prophylaxis with conventional recombinant factor VIII (rFVIII) and rFVIIIFc, an extended half-life rFVIII covalently fused to the Fc domain of human IgG1.",

author = "Erik Berntorp and C Negrier and P Gozzi and P-M Blaas and S Lethagen",

year = "2016",

doi = "10.1111/hae.12887",

language = "English",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.

AU - Berntorp, Erik

AU - Negrier, C

AU - Gozzi, P

AU - Blaas, P-M

AU - Lethagen, S

PY - 2016

Y1 - 2016

N2 - To use Pharmacokinetic (PK) simulations to illustrate potential differences in clinical outcomes between prophylaxis with conventional recombinant factor VIII (rFVIII) and rFVIIIFc, an extended half-life rFVIII covalently fused to the Fc domain of human IgG1.

AB - To use Pharmacokinetic (PK) simulations to illustrate potential differences in clinical outcomes between prophylaxis with conventional recombinant factor VIII (rFVIII) and rFVIIIFc, an extended half-life rFVIII covalently fused to the Fc domain of human IgG1.

U2 - 10.1111/hae.12887

DO - 10.1111/hae.12887

M3 - Article

C2 - 26863900

SN - 1351-8216

JO - Haemophilia

JF - Haemophilia

ER -

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this